NEJ026: Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations

被引：5

作者：

Maemondo, M. ^{[1
]}

Fukuhara, T. ^{[1
]}

Sugawara, S. ^{[2
]}

Takiguchi, Y. ^{[3
]}

Inoue, A. ^{[4
]}

Oizumi, S. ^{[5
]}

Ishii, Y. ^{[6
]}

Yoshizawa, H. ^{[7
]}

Isobe, T. ^{[8
]}

Gemma, A. ^{[9
]}

Morita, S. ^{[10
]}

Hagiwara, K. ^{[11
]}

Kobayashi, K. ^{[12
]}

Nukiwa, T. ^{[13
]}

机构：

[1] Miyagi Canc Ctr, Resp Med, Natori, Miyagi, Japan

[2] Sendai Kousei Hosp, Pulm Med, Sendai, Miyagi, Japan

[3] Chiba Univ, Sch Med, Dept Med Oncol, Chiba, Japan

[4] Tohoku Univ Hosp, Palliat Med, Sendai, Miyagi, Japan

[5] Hokkaido Canc Ctr, Resp Med, Sapporo, Hokkaido, Japan

[6] Dokkyo Med Univ, Pulm Med & Clin Immunol, Mibu, Tochigi, Japan

[7] Niigata Med Ctr Hosp, Resp Med, Niigata, Japan

[8] Shimane Univ, Fac Med, Med Oncol & Resp Med, Matsue, Shimane, Japan

[9] Main Hosp, Nippon Med Sch, Resp Med, Tokyo, Japan

[10] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan

[11] Jichi Med Univ, Pulm Med, Shimotsuke, Tochigi, Japan

[12] Saitama Med Univ, Int Med Ctr, Resp Med, Hidaka, Japan

[13] Japan AntiTB Assoc, Resp Med, Tokyo, Japan

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw383.86

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1286TiP

引用

页数：1

共 50 条

[1] Phase III study comparing bevacizumab plus erlotinib (BE) to erlotinib (E) in patients (pts) with untreated NSCLC harboring EGFR mutations: NEJ026
Kawashima, Y.
Fukuhara, T.
Furuya, N.
Saito, H.
Watanabe, K.
Iwasawa, S.
Tsunezuka, Y.
Yamaguchi, O.
Okada, M.
Yoshimori, K.
Nakachi, I.
Gemma, A.
Azuma, K.
Hagiwara, K.
Nukiwa, T.
Morita, S.
Kobayashi, K.
Maemondo, M.
ANNALS OF ONCOLOGY, 2018, 29 : 521 - 521
[2] Phase III study comparing bevacizumab plus erlotinib to erlotinib in patients with untreated NSCLC harboring activating EGFR mutations: NEJ026.
Furuya, Naoki
Fukuhara, Tatsuro
Saito, Haruhiro
Watanabe, Kana
Sugawara, Shunichi
Iwasawa, Shunichiro
Tsunezuka, Yoshio
Yamaguchi, Ou
Okada, Morihito
Yoshimori, Kouzou
Nakachi, Ichiro
Gemma, Akihiko
Azuma, Koichi
Hagiwara, Koichi
Nukiwa, Toshihiro
Morita, Satoshi
Kobayashi, Kunihiko
Maemondo, Makoto
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[3] NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.
Maemondo, Makoto
Fukuhara, Tatsuro
Saito, Haruhiro
Furuya, Naoki
Watanabe, Kana
Sugawara, Shunichi
Iwasawa, Shunichiro
Tsunezuka, Yoshio
Yamaguchi, Ou
Okada, Morihito
Yoshimori, Kouzou
Nakachi, Ichiro
Gemma, Akihiko
Azuma, Koichi
Hagiwara, Koichi
Nukiwa, Toshihiro
Morita, Satoshi
Kobayashi, Kunihiko
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[4] Evaluation of plasma EGFR mutation as an early predictor of response of erlotinib plus bevacizumab treatment in the NEJ026 study
Fukuhara, Tatsuro
Saito, Haruhiro
Furuya, Naoki
Watanabe, Kana
Sugawara, Shunichi
Iwasawa, Shunichiro
Tsunezuka, Yoshio
Yamaguchi, Ou
Okada, Morihito
Yoshimori, Kozo
Nakachi, Ichiro
Gemma, Akihiko
Azuma, Koichi
Kurimoto, Futoshi
Tsubata, Yukari
Fujita, Yuka
Nagashima, Hiromi
Asai, Gyo
Watanabe, Satoshi
Miyazaki, Masaki
Hagiwara, Koichi
Nukiwa, Toshihiro
Morita, Satoshi
Kobayashi, Kunihiko
Maemondo, Makoto
EBIOMEDICINE, 2020, 57
[5] CTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC
Zhou, Q.
Wu, Y-L.
Cheng, Y.
Liu, Y.
Chen, G.
Cui, J.
Yang, N.
Song, Y.
Li, X-L.
Lu, S.
Zhou, J.
Ma, Z.
Yu, S-Y.
Huang, C.
Shu, Y.
ANNALS OF ONCOLOGY, 2019, 30
[6] A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations
Saltos, Andreas N.
Creelan, Ben C.
Tanvetyanon, Tawee
Chiappori, Alberto A.
Antonia, Scott J.
Shafique, Michael R.
Ugrenovic-Petrovic, Milijana
Sansil, Samer
Neuger, Anthony
Ozakinci, Hilal
Boyle, Theresa A.
Kim, Jongphil
Haura, Eric B.
Gray, Jhanelle E.
LUNG CANCER, 2023, 183
[7] Neoadjuvant erlotinib in stage III NSCLC patients (pts) with activating EGFR mutations (EVENT trial).
Inal, Cengiz
Piperdi, Bilal
Keller, Steven M.
Halmos, Balazs
Stoopler, Mark
Limaye, Sewanti Atul
Levy, Benjamin Philip
Schneider, Bryan J.
Kim, Mimi
Sides, Jessica
Perez-Soler, Roman
Cheng, Haiying
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[8] Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial
Kawashima, Yosuke
Fukuhara, Tatsuro
Saito, Haruhiro
Furuya, Naoki
Watanabe, Kana
Sugawara, Shunichi
Iwasawa, Shunichiro
Tsunezuka, Yoshio
Yamaguchi, Ou
Okada, Morihito
Yoshimori, Kozo
Nakachi, Ichiro
Seike, Masahiro
Azuma, Koichi
Kurimoto, Futoshi
Tsubata, Yukari
Fujita, Yuka
Nagashima, Hiromi
Asai, Gyo
Watanabe, Satoshi
Miyazaki, Masaki
Hagiwara, Koichi
Nukiwa, Toshihiro
Morita, Satoshi
Kobayashi, Kunihiko
Maemondo, Makoto
LANCET RESPIRATORY MEDICINE, 2022, 10 (01): : 72 - 82
[9] Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
Saito, Haruhiro
Fukuhara, Tatsuro
Furuya, Naoki
Watanabe, Kana
Sugawara, Shunichi
Iwasawa, Shunichiro
Tsunezuka, Yoshio
Yamaguchi, Ou
Okada, Morihito
Yoshimori, Kozo
Nakachi, Ichiro
Gemma, Akihiko
Azuma, Koichi
Kurimoto, Futoshi
Tsubata, Yukari
Fujita, Yuka
Nagashima, Hiromi
Asai, Gyo
Watanabe, Satoshi
Miyazaki, Masaki
Hagiwara, Koichi
Nukiwa, Toshihiro
Morita, Satoshi
Kobayashi, Kunihiko
Maemondo, Makoto
LANCET ONCOLOGY, 2019, 20 (05): : 625 - 635
[10] Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Nonsquamous NSCLC Harboring EGFR Mutations
Zhao, Binghao
Xing, Hao
Ma, Wenbin
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : E76 - E77

← 1 2 3 4 5 →